RPL37P13

Across TCGA pan-cancer cohorts, RPL37P13 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL37P13’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL37P13 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL37P13 is over-expressed in tumor, although a few such as BRCA and KICH show the opposite, repressed pattern.

BRCA, LUSC, and LIHC are the cancer types where RPL37P13 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL37P13 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	II,III,IV	−0.064	.001	6	view →
LUSC	All	II,III,IV	+0.208	.003	4	view →
LIHC	All	All	+0.054	.008	4	view →
KICH	All	All	−0.116	.033	1	view →
KIRC	Female	All	−0.061	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RPL37P13–BRCA

Open the BRCA breakdown →